Physician profile
Ronald Vincent Mejzak
NPI 1447228507
$617.73
in general payments reported to CMS, 2019-2025
8 companies · $53.06 in 2025
The $53.06 reported for 2025 was less than what a typical Addiction Medicine (Anesthesiology) provider received nationally (typical 2025 total: $133).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.63 · 2022: $387 · 2023: $81.90 · 2024: $37.15 · 2025: $53.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $131.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $128.69 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $125.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $109.44 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $60.13 | 2022-2025 | Austedo Xr |
| Masimo Corporation | $26.76 | 2021 | |
| Neurocrine Biosciences, INC. | $18.73 | 2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Mejzak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.